Palvella Therapeutics Target Price

Analysts' average 12-month price target for Palvella Therapeutics is $230.

Get informed when a big investor buys or sells

+ Follow

Share Price

$157.24

Average Target Price

$232.25

47.7% upside

4 analysts in the last 4 months

High: $270 | Low: $207

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-08-05	Truist Financial	$207	31.6% upside
2026-08-05	Canaccord Genuity	$232	47.5% upside
2026-07-22	H.C. WainwrightAndrew Fein	$270	71.7% upside
2026-05-12	Stephens	$220	39.9% upside
2026-02-24	Truist Financial	$210	33.6% upside
2026-02-24	Chardan Capital	$210	33.6% upside
2026-02-24	Stifel Nicolaus	$250	59% upside
2026-02-24	H.C. Wainwright	$255	62.2% upside
2026-01-07	Mizuho Securities	$205	30.4% upside
2025-12-16	Canaccord GenuityWhitney Ijem	$204	29.7% upside
2025-12-16	Raymond JamesRyan Deschner	$193	22.7% upside
2025-12-15	Chardan Capital	$174	10.7% upside
2025-12-15	BTIGJeff Mukherjee	$192	22.1% upside
2025-12-15	Truist Financial	$190	20.8% upside
2025-12-15	UBSCatherine Novack	$143	9.1% downside
2025-12-15	H.C. Wainwright	$200	27.2% upside
2025-12-15	Cantor Fitzgerald	$210	33.6% upside
2025-12-15	Oppenheimer	$200	27.2% upside
2025-12-11	H.C. WainwrightAndrew Fein	$190	20.8% upside
2025-12-05	BTIG	$167	6.2% upside
2025-12-04	Craig-HallumAlbert Lowe	$175	11.3% upside
2025-11-24	Stifel NicolausSamimy Annabel	$145	7.8% downside
2025-11-19	Raymond James	$143	9.1% downside
2025-11-06	Cantor Fitzgerald	$200	27.2% upside
2025-10-09	Canaccord Genuity	$90	42.8% downside
2025-10-07	Cantor Fitzgerald	$120	23.7% downside
2025-10-02	Truist FinancialDanielle Brill	$80	49.1% downside
2025-09-25	H.C. Wainwright	$95	39.6% downside
2025-09-24	Stifel NicolausAnnabel Samimy	$80	49.1% downside
2025-09-09	Oppenheimer	$85	45.9% downside
2025-08-15	H.C. WainwrightAndres Maldonado	$75	52.3% downside
2025-08-05	Raymond James	$54	65.7% downside
2025-05-16	Canaccord GenuityWhitney Ijem	$52	66.9% downside
2025-03-25	Stifel NicolausAnnabel Samimy	$45	71.4% downside
2024-12-18	Cantor FitzgeraldJosh Schimmer	$30	80.9% downside

Palvella Therapeutics (PVLA) FAQ

Palvella Therapeutics (PVLA) currently reports a target price of $230. Use the charts on this page to explore Palvella Therapeutics's target price history and peer comparisons.

Analysts' average 12-month price target for Palvella Therapeutics is $230, about 47.7% upside from the current share price of $157.24. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $230, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Palvella Therapeutics, and consider following PVLA for alerts when major investors trade the stock.

Palvella Therapeutics is classified in the Healthcare sector. On target price, it currently shows $230. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PVLA with unrelated industries.